DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-one patent family members in twenty countries.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.
Seysara will be eligible for patent challenges on October 1, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 9, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for SEYSARA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Almirall||SEYSARA||sarecycline hydrochloride||TABLET;ORAL||209521-001||Oct 1, 2018||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|Almirall||SEYSARA||sarecycline hydrochloride||TABLET;ORAL||209521-003||Oct 1, 2018||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Almirall||SEYSARA||sarecycline hydrochloride||TABLET;ORAL||209521-002||Oct 1, 2018||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Almirall||SEYSARA||sarecycline hydrochloride||TABLET;ORAL||209521-002||Oct 1, 2018||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|